All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FDA classifies recall of Boston Scientific catheters as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of minimally invasive surgery as "most serious".
BSX Trades Near 52-Week High: Does the Stock Hold More Potential?
We believe Boston Scientific is one of those MedTech manufacturers that can be considered as the biggest gainers from the Fed's two successive interest rate cuts in 2024.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
Boston Scientific (BSX) closed the most recent trading day at $90.56, moving +0.4% from the previous trading session.
Boston Scientific (BSX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Boston Scientific (BSX) closed at $90.53 in the latest trading session, marking a -0.34% move from the prior day.
International Expansion Supports BSX Stock Amid Macroeconomic Woes
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology
Boston Scientific's new buyout is set to expand its interventional oncology offerings.
Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
